ATE301457T1 - Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor - Google Patents

Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor

Info

Publication number
ATE301457T1
ATE301457T1 AT96918465T AT96918465T ATE301457T1 AT E301457 T1 ATE301457 T1 AT E301457T1 AT 96918465 T AT96918465 T AT 96918465T AT 96918465 T AT96918465 T AT 96918465T AT E301457 T1 ATE301457 T1 AT E301457T1
Authority
AT
Austria
Prior art keywords
inhibitor
cyclooxygenase
agent containing
lipoxygenase
lipoxygenase inhibitor
Prior art date
Application number
AT96918465T
Other languages
English (en)
Inventor
Peter C Isakson
Gary D Anderson
Susan A Gregory
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE301457T1 publication Critical patent/ATE301457T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96918465T 1995-06-12 1996-06-11 Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor ATE301457T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48947295A 1995-06-12 1995-06-12
PCT/US1996/010106 WO1996041626A1 (en) 1995-06-12 1996-06-11 Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor

Publications (1)

Publication Number Publication Date
ATE301457T1 true ATE301457T1 (de) 2005-08-15

Family

ID=23944013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918465T ATE301457T1 (de) 1995-06-12 1996-06-11 Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor

Country Status (9)

Country Link
US (1) US6136839A (de)
EP (1) EP0833622B8 (de)
JP (1) JPH11507670A (de)
AT (1) ATE301457T1 (de)
AU (1) AU6111796A (de)
CA (1) CA2224517A1 (de)
DE (1) DE69635048T2 (de)
ES (1) ES2247604T3 (de)
WO (1) WO1996041626A1 (de)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3201095A (en) * 1994-07-27 1996-02-22 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1997029774A1 (en) 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
ES2169351T3 (es) 1996-02-13 2002-07-01 Searle & Co Combinaciones que tienen efectos inmunosupresores, que contienen inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
PT914122E (pt) * 1996-07-11 2003-12-31 Warner Lambert Co Metodo para o tratamento e prevencao de disturbios neurodegenerativos atraves da administracao de uma tiazolidinona
CA2283399C (en) * 1997-03-14 2006-02-21 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
BR9807920A (pt) * 1997-04-03 2000-02-22 Searle & Co Processos para tratamento de uma demência em um sujeito e para prevenção de uma demência
EE9900517A (et) * 1997-04-18 2000-06-15 G.D. Searle & Co. Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südameveresoonkonna haiguste ärahoidmiseks
KR100382619B1 (ko) * 1997-09-05 2003-05-09 글락소 그룹 리미티드 2,3-디아릴-피라졸로[1,5-ｂ]피리다진 유도체, 그의 제조방법 및 시클로옥시게나제 2(ｃｏｘ-2) 억제제로서의 용도
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
TW587079B (en) * 1998-09-25 2004-05-11 Almirall Prodesfarma Ag 2-phenylpyran-4-one derivatives
KR20010075673A (ko) 1998-11-03 2001-08-09 그레이엄 브레레톤, 레슬리 에드워즈 선택적 ｃｏｘ-2 억제제로서의 피라졸로피리딘 유도체
AU2661400A (en) 1999-02-27 2000-09-21 Glaxo Group Limited Pyrazolopyridines
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
DE10001166A1 (de) * 2000-01-13 2001-07-19 Merckle Gmbh Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
IN191512B (de) * 2000-01-21 2003-12-06 Panacea Biotech
US6589557B2 (en) * 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
US6800297B2 (en) 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
AU2002222910A1 (en) * 2000-07-13 2002-01-30 Bristol-Myers Squibb Company Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US8680081B2 (en) * 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine
ATE301653T1 (de) 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridine
ES2243579T3 (es) * 2000-12-15 2005-12-01 Glaxo Group Ltd Derivados de pirazolopirideno.
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
WO2002072581A2 (en) * 2001-03-08 2002-09-19 Smithkline Beecham Corporation Pyrazolopyriadine derivatives
JP4237497B2 (ja) * 2001-03-30 2009-03-11 スミスクライン ビーチャム コーポレーション ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用
US20050107400A1 (en) * 2001-03-30 2005-05-19 Boyd Leslie F. Use of pyrazolopyridines as therapeutic compounds
US7141569B2 (en) * 2001-04-10 2006-11-28 Smithkline Beecham Corporation Antiviral pyrazolopyridine compounds
AU2002303406B2 (en) 2001-04-18 2006-03-30 Euro-Celtique S.A. Nociceptin analogs
JP4489354B2 (ja) 2001-04-18 2010-06-23 ユーロ−セルティーク エス．エイ． スピロインデンおよびスピロインダン化合物類
SI1975164T1 (sl) 2001-04-18 2010-05-31 Euro Celtique Sa Oktahidrobenzimidazolonske spojine kot analgetiki
PT1598340E (pt) 2001-04-18 2009-04-13 Euro Celtique Sa Derivados de 1-(4-piperidinil)-1,3-di-hidro-2h-benzoxazole- 2-ona e compostos relacionados como análogos de nociceptina e ligandos orl1 para o tratamento da dor
JP2004527560A (ja) 2001-04-27 2004-09-09 スミスクライン ビーチャム コーポレーション ピラゾロ［１，５−α］ピリジン誘導体
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
BR0210464A (pt) * 2001-06-21 2004-07-20 Smithkline Beecham Corp Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
JP2005507878A (ja) * 2001-09-07 2005-03-24 スミスクライン ビーチャム コーポレーション ヘルペス感染症を治療するためのピラゾロ−ピリジン類
JP3605105B2 (ja) * 2001-09-10 2004-12-22 キヤノン株式会社 電子放出素子、電子源、発光装置、画像形成装置および基板の各製造方法
EP1432712B1 (de) * 2001-10-05 2006-05-17 SmithKline Beecham Corporation Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
ES2292839T3 (es) * 2001-12-11 2008-03-16 Smithkline Beecham Corporation Derivados de pirazolo-piridina como agentes contra el herpes.
EP2033951A3 (de) 2002-02-01 2009-12-23 Euro-Celtique S.A. 2-Piperazin-Pyridine zur Schmerzbehandlung
BR0309014A (pt) * 2002-04-08 2005-01-11 Glaxo Group Ltd ácido(2-((2-alcóxi)-fenil)-ciclopent-1-enil)carbo e heterocìclico aromático e derivados
EP1927858B1 (de) 2002-04-29 2013-01-09 Euro-Celtique S.A. Konformativ eingeschränkte Peptide zur Bindung des ORL-1-Rezeptors
AU2003227710A1 (en) * 2002-05-07 2003-11-11 Altana Pharma Ag New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
BR0310068A (pt) * 2002-05-17 2005-03-08 Merckle Gmbh Uso de um ou mais de um composto, combinação, e, composição farmacêutica
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
AU2003260025A1 (en) * 2002-08-26 2004-03-11 Merck & Co., Inc. Method for the prevention and/or treatment of atherosclerosis
AU2003275266A1 (en) * 2002-10-03 2004-05-04 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
CA2502357A1 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
GB0225548D0 (en) * 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2004052374A1 (en) * 2002-12-12 2004-06-24 Altana Pharma Ag Combination medicament
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
EP1594847A2 (de) * 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituierte azolderivate zur therapeutischen verwendung
MXPA05011200A (es) * 2003-04-18 2005-12-14 Memory Pharm Corp Derivados de pirazol como inhibidores de fosfodiesterasa 4.
DE602004002832T2 (de) * 2003-05-07 2007-06-06 Osteologix A/S Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
DK2266584T3 (da) * 2003-05-07 2013-01-02 Osteologix As Sammensætning med strontium og D-vitamin til profylakse og/eller behandling af brusk- og knogletilstande
AR044688A1 (es) 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
EP1641775B1 (de) * 2003-07-03 2009-02-18 Euro-Celtique S.A. 2-pyridin alkyne derivaten und ihre verwendung für die schmerzbehandlung
EP1972340A3 (de) 2003-07-10 2008-11-26 Arturo Jimenez Bayardo Verfahren für die Zubereitung einer wässrigen Meloxicam-Lösung und auf diese Weise hergestellte wässrige Lösung
PL1867644T3 (pl) 2003-07-24 2009-10-30 Euro Celtique Sa Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
MXPA06000940A (es) * 2003-07-24 2006-03-30 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento de dolor.
KR100977242B1 (ko) 2003-07-24 2010-08-24 유로-셀띠끄 소시에떼 아노님 피페리딘 화합물 및 그들을 포함하는 약학적 조성물
AU2004261666B2 (en) * 2003-08-01 2009-06-18 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2005025578A1 (en) * 2003-09-16 2005-03-24 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases
CA2537010A1 (en) 2003-09-22 2005-04-07 Euro-Celtique S.A. Phenyl - carboxamide compounds useful for treating pain
JP4630871B2 (ja) * 2003-09-22 2011-02-09 ユーロ−セルティーク エス．エイ． 疼痛を治療するのに有用な治療薬
US20060079566A1 (en) 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
GB0323585D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323581D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Novel compounds
GB0323584D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
DE10351035A1 (de) * 2003-10-31 2005-05-25 Merckle Gmbh Chemisch Pharmazeutische Fabrik Pharmazeutische Licofelone-Formulierung
CN1905870A (zh) 2003-11-21 2007-01-31 康宾纳特克斯公司 用于治疗炎性病症的方法和试剂
EA200601249A1 (ru) * 2003-12-30 2007-02-27 Еуро-Селтик С. А. Пиперазины, пригодные для лечения боли
EP1730118A1 (de) * 2004-02-12 2006-12-13 Transtech Pharma, Inc. Substituierte azolderivate, zusammensetzungen und anwendungsverfahren
WO2005102354A1 (en) * 2004-04-20 2005-11-03 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
GB0410121D0 (en) * 2004-05-06 2004-06-09 Glaxo Group Ltd Compounds
CA2570389A1 (en) * 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
US7534806B2 (en) * 2004-12-06 2009-05-19 Avigen, Inc. Method for treating neuropathic pain and associated syndromes
NZ556163A (en) * 2005-01-10 2011-11-25 Univ California Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors
KR101364762B1 (ko) * 2005-02-17 2014-02-17 신타 파마슈티칼스 코프. 증식성 장애의 치료를 위한 화합물
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2007028638A1 (en) 2005-09-09 2007-03-15 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
US20080319020A1 (en) 2005-11-21 2008-12-25 Purdue Pharma L.P. 4-Oxadiazolyl-Piperidine Compounds and Use Thereof
NL2000351C2 (nl) * 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
ZA200805648B (en) * 2006-01-30 2009-09-30 Transtech Pharma Inc Substituted imidazole derivatives and their use as PTPase inhibitors
WO2007085357A1 (en) * 2006-01-30 2007-08-02 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
JP5539717B2 (ja) * 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
TWI381838B (zh) 2006-11-01 2013-01-11 Purdue Pharma Lp 苯基丙醯胺化合物及其應用
JP5462633B2 (ja) * 2007-01-16 2014-04-02 パーデュー、ファーマ、リミテッド、パートナーシップ 複素環置換ピペリジン化合物とその使用
DK2131841T3 (da) * 2007-01-30 2012-10-15 Avigen Inc Fremgangsmåder til behandling af akut smerte
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
ME02123B (me) 2007-04-27 2014-08-29 Purdue Pharma Lp Antagonisti trpv1 i njihova upotreba
CA2685121A1 (en) 2007-04-27 2008-11-06 Purdue Pharma L.P. Therapeutic agents useful for treating pain
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
US7853320B1 (en) 2007-05-31 2010-12-14 Purdue Pharma L.P. Transdermal device having mechanical assist for porator-to-skin contact
US8095213B1 (en) 2007-05-31 2012-01-10 Purdue Pharma L.P. Transdermal patch
ES2422603T3 (es) * 2007-05-31 2013-09-12 Shionogi & Co Compuestos oxiimino y el uso de estos
US8214031B1 (en) 2007-05-31 2012-07-03 Purdue Pharma L.P. Switch for transdermal patch
US20110190300A1 (en) 2007-05-31 2011-08-04 Akira Matsumura Amide compounds and the use thereof
US8047399B1 (en) 2007-07-05 2011-11-01 Purdue Pharma L.P. Dispenser for transdermal devices
AU2008274941A1 (en) 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
CA2697051C (en) 2007-08-31 2013-12-17 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2009059307A1 (en) * 2007-11-01 2009-05-07 Washington University In St. Louis Compositions and methods for treating pruritus
NZ586058A (en) 2007-11-30 2013-11-29 Purdue Pharma Lp Benzomorphan compounds
WO2009087564A1 (en) 2008-01-08 2009-07-16 Purdue Pharma L.P. Proline analogs as ligands for cannabinoid receptors for the treatment of pain
US8518934B2 (en) * 2008-06-11 2013-08-27 Shonogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
TWI403506B (zh) * 2008-06-16 2013-08-01 Faes Farma Sa 用於治療急性和慢性發炎疾病之５－（４－甲磺醯基－苯基）－噻唑衍生物類
CN102143736A (zh) 2008-07-17 2011-08-03 梅里亚有限公司 增强聚原酸酯和它们的制剂的稳定性的方法
ES2393849T7 (es) 2008-07-21 2015-01-28 Purdue Pharma Lp Compuestos de piperidina puenteada, de tipo quinoxalina sustituida, y usos de los mismos
US8530494B2 (en) 2008-07-30 2013-09-10 Purdue Pharma Lp Buprenophine analogs
US8324249B2 (en) * 2008-08-01 2012-12-04 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8546388B2 (en) * 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
JP5643222B2 (ja) 2009-04-02 2014-12-17 塩野義製薬株式会社 アクリルアミド化合物およびその使用
US20120108823A1 (en) 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
US20100273203A1 (en) * 2009-04-23 2010-10-28 Board Of Trustees Of The University Of Arkansas Methods and compositions for detecting metabolites
BRPI1014405A2 (pt) 2009-04-29 2016-04-05 Amarin Corp Plc composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso
US8410064B2 (en) * 2009-08-24 2013-04-02 The Board Of Trustees Of The University Of Arkansas Classical cannabinoid metabolites and methods of use thereof
US8883218B2 (en) * 2010-03-26 2014-11-11 The Board Of Trustees Of The University Of Arkansas Anti-cancer nanoparticle compositions and methods of use
WO2011158108A2 (en) 2010-06-16 2011-12-22 Purdue Pharma L.P. Aryl substituted indoles and the use thereof
US9279003B2 (en) 2010-07-07 2016-03-08 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
US9120752B2 (en) 2010-07-16 2015-09-01 Purdue Pharma, L.P. Pyridine compounds as sodium channel blockers
AU2011303597A1 (en) 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
CN103168033A (zh) 2010-10-05 2013-06-19 普渡制药公司 作为钠通道阻断剂的喹唑啉化合物
US9079899B2 (en) 2010-11-01 2015-07-14 The Ohio State University Anti-staphylococcal celecoxib derivatives
AU2011346749A1 (en) 2010-12-22 2013-05-02 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
KR20130119964A (ko) 2010-12-22 2013-11-01 퍼듀 퍼머 엘피 나트륨 채널 차단제로서의 치환된 피리딘
US9095598B2 (en) 2010-12-28 2015-08-04 The Board Of Trustees Of The University Of Arkansas Stilbenoid derivatives and their uses
US9161894B2 (en) * 2011-03-01 2015-10-20 Npharmakon, Llc Use of N-(4-methoxyphenyl)-1-phenyl-1H-pyrazol-3-amine and related compounds
WO2012129495A1 (en) 2011-03-23 2012-09-27 Trevena, Inc. Opioid receptor ligands and methods of using and making same
EP2723732B1 (de) 2011-06-22 2017-01-18 Purdue Pharma LP Trpv1-antagonisten mit dihydroxy-substituent und ihre verwendung
US8957024B2 (en) 2011-07-27 2015-02-17 Washington University Composition and methods for reducing opioid-induced pruritus
US9394293B2 (en) 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
ME02873B (de) 2011-09-02 2018-04-20 Purdue Pharma Lp Pyrimidine als natriumkanalblocker
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013064883A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
ES2583146T3 (es) 2011-12-01 2016-09-19 Purdue Pharma L.P. Compuestos de piperidina de tipo quinoxalina sustituidos con azetidina y usos de éstos
WO2013084060A1 (en) 2011-12-08 2013-06-13 Purdue Pharma L.P. Quaternized buprenorphine analogs
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
AR091027A1 (es) 2012-05-11 2014-12-30 Purdue Pharma Lp Analogos de benzomorfano y el usos de estos
US9718865B2 (en) 2012-07-27 2017-08-01 Purdue Pharma L.P. Sodium channel blocking peptides and the use thereof
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
TW201431842A (zh) 2012-11-09 2014-08-16 Purdue Pharma Lp 苯並嗎啡烷類似物及其應用
WO2014087226A1 (en) 2012-12-07 2014-06-12 Purdue Pharma L.P. Buprenorphine analogs as opiod receptor modulators
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014102588A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
WO2014102590A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
US9040533B2 (en) 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
JP6182620B2 (ja) 2013-01-31 2017-08-16 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体およびその使用
CN105491885B (zh) 2013-03-07 2018-09-25 思想实验室有限责任公司 疼痛药物组合及其用途
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
WO2014145116A2 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
WO2015044759A1 (en) 2013-09-24 2015-04-02 Purdue Pharma L.P. Treatment of burn pain by trpv1 modulators
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
CA2977367A1 (en) 2015-02-19 2016-08-25 Purdue Pharma L.P. Methods and compositions for decreasing gastric emptying
WO2016133788A1 (en) 2015-02-20 2016-08-25 The Regents Of The University Of California Methods of inhibiting pain
AU2016372028B2 (en) 2015-12-14 2022-02-17 Trevena, Inc. Methods of treating hyperalgesia
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
EP3681479B1 (de) * 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Natriumhydrogencarbonat zur verwendung in der behandlung von gicht und verwandten erkrankungen
CA3080818A1 (en) 2017-10-30 2019-05-09 Montreal Heart Institute Methods of treating elevated plasma cholesterol
WO2019097080A1 (en) 2017-11-20 2019-05-23 Kiakos Konstantinos 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
US11251635B2 (en) 2017-12-19 2022-02-15 Welch Allyn, Inc. Vital signs monitor with a removable and dischargable battery
US11576913B2 (en) 2018-01-24 2023-02-14 Purdue Pharma L.P. Sleep disorder treatment and prevention
EP4124336B1 (de) 2021-07-30 2023-10-25 Cannamedical Pharma GmbH Transmukosales pflaster mit einem cannabinoid und/oder einem opioid

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472420A (en) * 1983-08-18 1984-09-18 Methodist Hospital Of Indiana, Inc. Method for treatment of shock
US4760086A (en) * 1985-02-27 1988-07-26 Merck & Co., Inc. N-alkenyl-3-hydroxybenzo[b]thiophene-2-carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
EP0178035B1 (de) * 1984-05-12 1990-01-03 FISONS plc Antiinflammatorische 1,N-Diarylpyrazol-3-amine, deren Zusammensetzungen und Verfahren zu deren Herstellung
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US4769461A (en) * 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
US4873259A (en) * 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
AU611437B2 (en) * 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
US5242940A (en) * 1987-05-29 1993-09-07 Ortho Pharmaceutical Corporation Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same
WO1988009675A1 (en) * 1987-06-05 1988-12-15 Medicis Corporation Inhibition of arachidonic acid metabolism
PL154186B1 (en) * 1987-07-15 1991-07-31 Wellcome Found Method for manufacturing arylic derivatives of the hydroxamic acid
US4870210A (en) * 1987-12-18 1989-09-26 American Home Products Corporation Aminoguanidine derivative as anti-inflammatory agents
US5112868A (en) * 1988-05-19 1992-05-12 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
EP0351214A1 (de) * 1988-07-14 1990-01-17 The Wellcome Foundation Limited Entzündungshemmende Arylderivate
GB8927287D0 (en) * 1988-12-23 1990-01-31 Ici Plc Cyclic ether derivatives
US5234950A (en) * 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
HU217072B (hu) * 1989-01-10 1999-11-29 Pfizer Inc. 1-Heteroaril-oxindol-3-karboxamid-származékok, azok előállítása, és az azokat tartalmazó gyógyszerkészítmények
US5066668A (en) * 1989-06-09 1991-11-19 Warner-Lambert Co. Triazole derivatives of fenamates as antiinflammatory agents
JPH06759B2 (ja) * 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
JPH05502233A (ja) * 1989-12-16 1993-04-22 アストラ・フアーマシユウテイカルズ・リミテツド 薬理学的に活性なアミドカルボキシレート誘導体
JPH0717589B2 (ja) * 1990-01-22 1995-03-01 ファイザー製薬株式会社 新規１，３―ジカルボニル化合物およびその組成物
JPH0729998B2 (ja) * 1990-01-22 1995-04-05 ファイザー製薬株式会社 新規ベンゾキノン化合物およびその組成物
US5017604A (en) * 1990-04-11 1991-05-21 Warner-Lambert Company Novel fenamic acid methyl hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US5220059A (en) * 1990-04-19 1993-06-15 Abbott Laboratories Lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids
GB9012936D0 (en) * 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
JPH05508153A (ja) * 1990-06-12 1993-11-18 スミスクライン・ビーチャム・コーポレイション ５―リポキシゲナーゼ経路およびシクロオキシゲナーゼ経路で媒介される疾患の阻害
US5476873A (en) * 1990-07-25 1995-12-19 Abbott Laboratories Acetylene derivatives having lipoxygenase inhibitory activity
ATE144247T1 (de) * 1990-07-25 1996-11-15 Abbott Lab Acetylenderivate mit lipoxygenase inhibitorischer wirkung
JPH04134077A (ja) * 1990-09-21 1992-05-07 Taiho Yakuhin Kogyo Kk イソオキサゾール化合物
IE913655A1 (en) * 1990-11-06 1992-05-22 Zeneca Ltd Synergistic agents
DE4037426A1 (de) * 1990-11-24 1992-05-27 Kali Chemie Pharma Gmbh Piperidinoalkylbenzoxazin- und -thiazin-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0563286A4 (en) * 1990-12-13 1995-01-11 Smithkline Beecham Corp Novel csaids
CA2365269A1 (en) * 1991-01-31 1992-08-20 Warner-Lambert Company Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
US5177079A (en) * 1991-01-31 1993-01-05 Warner-Lambert Company 2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
AU1361592A (en) * 1991-03-05 1992-10-06 Tsumura & Co. Novel allyl alcohol derivative
CA2102209C (en) * 1991-05-01 1997-11-18 Takashi Shindo Novel isoxazole derivative and salt thereof
FR2677355B1 (fr) * 1991-06-06 1993-08-20 Bellon Labor Sa Roger Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5270319A (en) * 1991-09-09 1993-12-14 Warner-Lambert Company 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents
EP0746324A1 (de) * 1991-09-13 1996-12-11 Boron Biologicals, Inc. Verfahren zur bekämpfung von osteoporose und anderen krankheitszuständen bei säugern unter verwendung von organischen borverbindungen
US5476944A (en) * 1991-11-18 1995-12-19 G. D. Searle & Co. Derivatives of cyclic phenolic thioethers
US5354865A (en) * 1992-09-10 1994-10-11 Abbott Laboratories Phenylmethyl derivatives having lipoxygenase inhibitory activity
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
ATE160345T1 (de) * 1993-01-15 1997-12-15 Searle & Co 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
GB9308652D0 (en) * 1993-04-27 1993-06-09 Wellcome Found Anti-inflammatory compounds
EP0696272A1 (de) * 1993-04-27 1996-02-14 The Wellcome Foundation Limited Cyclooxygenase und 5-lipoxygenase hemmende n[3-biphenylyl-1(5)-methyl-2-propenyl] acetohydroxamsäure-derivate
WO1994026731A1 (en) * 1993-05-13 1994-11-24 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
GB9312204D0 (en) * 1993-06-14 1993-07-28 Zeneca Ltd Therapeutic composition
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5298521A (en) * 1993-08-30 1994-03-29 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
ES2172959T3 (es) * 1993-11-30 2002-10-01 Searle & Co Pirazolil-bencenosulfonamidas triciclicas, sustituidas y su uso como inhibidores de ciclooxigenasa ii.
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs

Also Published As

Publication number Publication date
WO1996041626A1 (en) 1996-12-27
EP0833622A1 (de) 1998-04-08
JPH11507670A (ja) 1999-07-06
US6136839A (en) 2000-10-24
ES2247604T3 (es) 2006-03-01
EP0833622B1 (de) 2005-08-10
DE69635048T2 (de) 2006-02-16
CA2224517A1 (en) 1996-12-27
DE69635048D1 (de) 2005-09-15
AU6111796A (en) 1997-01-09
EP0833622B8 (de) 2005-10-12

Similar Documents

Publication Publication Date Title
ATE301457T1 (de) Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
ATE322893T1 (de) Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten
NO964966L (no) Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav
NO20001830L (no) Ny kombinasjon
DE69014030T3 (de) Mittel für die Verhütung und Behandlung von Diarrhöe.
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
TR199801930T2 (xx) 6-Fenilpiridil-2-amin t�revleri.
DK0827537T3 (da) Chromatin-regulator-gener
EP0813544A4 (de)
BR9713522A (pt) Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
DE69427485D1 (de) Verbindungen, zubereitungen und behandlung von allergien und entzündungen
WO1998018440A3 (fr) Utilisation des inhibiteurs de l'activite de l'acide retinoique pour traiter les peaux sensibles
AU1278600A (en) Novel therapeutic application of nicergoline
ATE28188T1 (de) Antikonvulsive mittel.
DE69608683D1 (de) Analytisches und therapeutisches mittel
MX9601031A (es) Composicion farmaceutica para el tratamiento y prevencion del cancer de prostata.
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ES2173180T3 (es) Derivados del mercaptoacetilamida hipocolesterolemicos, antiateroescleroticos e hipotrigliceridemicos.
ATE213644T1 (de) Kombinationstherapie für die behandlung von arthritis erkrankungen
NO963988L (no) Hypokolesterolemiske-, antiatherosklerotiske-, og hypotriglyceridemiske mercaptoacetylamidderivater
PT1133297E (pt) Nova aplicacao terapeutica da 1,6-dimetil-8beta-hidroximetil-10alfa-metoxiergolina
GEU1998400Y (en) Ointment “Topokril” for Treating of Dermatitis
FR2708283B1 (fr) Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.
UA32146A (uk) Спосіб оцінки ефективності лікування пародонтита

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties